Equillium, Inc. Board of Directors

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Mr. Bruce D. Steel C.F.A.

Mr. Bruce D. Steel C.F.A.

Co-Founder, President, CEO & Director

Penny Tom

Penny Tom

Senior VP of Finance & Principal Accounting Officer

Mr. Joel M. Rothman

Mr. Joel M. Rothman

Chief Development Officer

Mr. Michael Moore

Mr. Michael Moore

Vice President of Investor Relations & Corporate Communications

Mr. Jason A. Keyes

Mr. Jason A. Keyes

Chief Financial Officer

Dr. Stephen Connelly Ph.D.

Dr. Stephen Connelly Ph.D.

Chief Scientific Officer & Director

Dr. Matthew Ritter Ph.D.

Dr. Matthew Ritter Ph.D.

Senior Vice President of Corporate Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.